These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Manus_Nat Med_NOVOAB_ChemRxiv.pdf (563.32 kB)

Fast Restoration of a Broad-Spectrum SARS-Cov Therapeutic Antibody for SARS-Cov-2

revised on 11.09.2020, 16:41 and posted on 14.09.2020, 06:24 by Sara Zhang, Mike Young, Jason Pan

The rapid spread of SARS-Cov-2 remains a major threat for public health and global economy, both preventative and therapeutic solutions are therefore urgently needed. Through the use of epitope-guided antibody design, we successfully restored a broad-spectrum SARS-Cov therapeutic antibody for SARS-Cov-2. Compared to the precursor antibody CR3022, the newly designed antibody NOVOAB-20 binds to SARS-Cov-2 receptor binding domain (RBD) with a more than 10-fold higher affinity. Because this antibody targets a highly conserved epitope and the mutations on SARS-Cov-2 known so far are all not in this region, it also has the potential to block future SARS-Cov-2 mutants. As a fully humanized antibody, NOVOAB-20 is a promising candidate to be developed as potential therapeutics for SARS-Cov-2, either as monotherapy or in combination with other neutralizing antibodies targeting different epitopes (e.g. the ACE2 binding site).


Email Address of Submitting Author


NovoAb Bioanalytics, Inc.



ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest

Version Notes

Manus_Nature Med_NOVOAB_ChemRxiv_v1